Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
Date:5/19/2008

n and repair, may provide an early indication of a biological response to this therapy."

"These data, and other clinical and preclinical observations of natural mobilization of stem cells in a response to our ZFP activator of VEGF, are very interesting and form the basis of our most recently initiated Phase 2 study (SB-509-703)," commented Dale Ando, M.D. Sangamo's vice president of therapeutic development and CMO. "In this Phase 2 clinical trial we are monitoring changes in the numbers of stem cells in the circulation of subjects with mild to moderate diabetic neuropathy after treatment with our ZFP Therapeutic. We believe that the study may provide us with valuable pharmacodynamic data on the relationship between stem cell mobilization and treatment."

Clinical Results Presented at the ISCT Meeting

The data presented at the ISCT meeting on Sunday, May 18, 2008, were collected from a single arm, open-label, Phase 1 clinical trial in subjects (n=20) with critical limb ischemia (Rutherford Grade 4/5). Qualifying subjects were assigned to receive dose-escalating, intra-muscular injections of ZFP-VEGF in the ischemic leg (index leg). Subjects were clinically classified as significant responders, minimal responders or non-responders based on their tissue oximetry readings. Circulating progenitor cells were measured and quantitated by FACS analysis based on aldehyde dehydrogenase activity (ALDH+) and expression of CD34 in 11 subjects. These measures were subsequently compared with clinical outcomes. Additionally, bone marrow samples from 8 patients were evaluated for ALDH+ cells on Day 0 and Day 12 post treatment to determine the effects of ZFP-VEGF on progenitor cell mobilization.

Clinicians observed a mean increase in circulating CD34+/ ALDH + cells of 1.3 fold from Day 0 to Day 30 post-treatment and 1.9 fold from Day 0 to Day 90 post-treatment. In addition, subjects with 7 to 9 fold increases in bone marrow stem cells were also the best clin
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
2. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
3. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
4. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
5. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
6. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
9. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
10. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
11. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
(Date:12/15/2014)... BEIJING , Dec. 15, 2014  Origin Agritech Limited ... "), a technology-focused supplier of crop seeds in ... results for its fiscal year 2014 ended September 30, 2014, ... The Company will host a teleconference on January 8, ... Beijing time to discuss the results. To participate ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Than rituximab ... in a Pre-Clinical Study, ... that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing complement dependent cytotoxicity ... study. The CD20,antibodies were incubated with tumor cells and analyzed ...
... Prize winner Richard Feynman presented a talk entitled There,s Plenty ... was no physical reason why humans couldn,t manipulate atoms. ... the new atom positions remains. How do you know ... 7, 2007 issue of Science, IBM and Imago have taken ...
... Chief Financial Officer and James Weaver as Chairman, ... ILI ) announced today that Thomas Gerson has been ... Weaver as,Chairman of the Board of Directors. In addition, ... and Development. "We are pleased to welcome Tom ...
Cached Biology Technology:Genmab Announces Encouraging Preclinical Data for ofatumumab 2IBM and Imago find a crucial difficulty in semiconductor device scaling 2Interleukin Genetics Announces Management and Board Appointments 2Interleukin Genetics Announces Management and Board Appointments 3Interleukin Genetics Announces Management and Board Appointments 4
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Six researchers from the Technische Universitaet Muenchen are ... bring around ten million euros to support pioneering ... investigate the impact of extreme weather events on ... magnetic vortices for enhanced data processing. Prof. Rdiger ...
... among South Asians to be recalculated has been published by ... from the University,s Departments of Health Sciences and Cardiovascular Sciences ... Asians should be classed as obese to be redefined. ... a journal of the Public Library of Science. South ...
... 2004 as a three-person start-up may well be on ... Advanced by a team of young Dutch scientists pushing ... is attracting the attention of some key investors and ... to innovative SMES, with the Eurostars funding programme leading ...
Cached Biology News:10 million euros for pioneering research projects at TU Muenchen 210 million euros for pioneering research projects at TU Muenchen 310 million euros for pioneering research projects at TU Muenchen 410 million euros for pioneering research projects at TU Muenchen 510 million euros for pioneering research projects at TU Muenchen 610 million euros for pioneering research projects at TU Muenchen 7New research calls for lower limit to be set for South Asian obesity level 2Biotech start-up brings DNA-sequencing to the medical market 2Biotech start-up brings DNA-sequencing to the medical market 3
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Biology Products: